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What is it?
A malignant, multifocal systemic 
disease that originates from the 
vascular endothelium. 
Clinical forms
Classic 
Immunosuppression 
Endemic African 
Epidemic HIV-associated 
Etiology
Infection with human herpes virus-8 
(HHV-8), which is transmitted 
sexually or via blood or saliva.  
(Andreoni et al. 2002).

HAART  decreased KS  
90% in the Department of 
Dermatovenereology at Frankfurt 
Univ Hosp , and the clinical course 
of disease has improved 
significantly 
Signs, symptoms and diagnosis
In contrast to the classical KS found in older men, 
in whom the tumors usually occur on the lower 
legs and feet, HIV-associated KS does not have 
a preferential pattern of localization.  
Staging
HISTOLOGY?
HHV-8, can be detected in 
tumor tissue by PCR. 
Antibodies are often 
detected months before the 
clinical manifestation of the 
tumor 
Neutralizing antibodies
Are protective (Kimball 2004)
In patients with KS the titres of 
neutralizing antibodies are low. 
Treatment
If the HIV viral load can be reduced (ideally 
below the level of detection) and immune 
reconstitution is achieved with increase in 
CD4 cell count,KS resolves except certain PIs:
Indinavir,Saquinavir,and Ritonavir
CHEMOTHERAPY
Liposomal 
anthracyclines are  first 
line.
Paclitaxel or  (ABV 
regimen) are second 
line. 
RESPO
NSE
COMP
LETE
PARTI
AL
NONE ID TOTA
L
Male 8 17 17 28 70
Female 3 12 4 9 28
Total 11 29 21 37 98
CD4 CELLS
 Males mean 222/l
 Females mean 160/l
 Does male gender predispose to KS?
RESPO
NSE
COMPL
ETE
PARTIA
L
NONE ID
AGE(YR
S)
39
(27-60)
35
(24-48)
35
(28-52)
38
(24-57)
CD4 261
(35-581)
307
(35-573)
186
(6-513)
142
(6-531)
AGE
 No association here.
 CD4 CELL COUNT BELOW 
200/l,maybe.
Location
RESPO
NSE
COMPL
ETE
PARTIA
L
NONE ID
LOWER
LIMB
4 6 10 8
PALATE 3 1 3
GENER
ALISED
4 23 1O 26
Side Effects and Courses
RESPON
SE
COMPLE
TE
PARTIAL NONE ID
NEUTR
OPENIA
0 8 16 11
NUMBE
R OF 
COURSE
S
6
(4-8)
6
(4-10)
7
(3-9)
2
(1-5)
Predicting    outcome
 NEUTROPENIA
 CD4 CELL COUNT >200/l
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